Incyte Advances Pivotal Clinical Trial Program for Ruxolitinib

Incyte said late Friday said the first patient has been treated in the pivotal phase 2 trial testing ruxolitinib (Jakafi) on steroid-refractory acute graft-versus-host disease (GVHD).

Ruxolitinib was previously granted breakthrough therapy designation by the U.S. Food and Drug Administration, being a product candidate for serious or life-threatening condition such as GVHD. It was also given the orphan drug designation for being a product candidate for a rare disease.